NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis $2.56 +0.01 (+0.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.51▼$2.6350-Day Range$2.06▼$3.2352-Week Range$1.35▼$4.27Volume54,474 shsAverage Volume154,655 shsMarket Capitalization$159.10 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Galectin Therapeutics alerts: Email Address Galectin Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside329.7% Upside$11.00 Price TargetShort InterestBearish10.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 3 Articles This WeekInsider TradingAcquiring Shares$3,520 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.66) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.52 out of 5 starsMedical Sector726th out of 936 stocksPharmaceutical Preparations Industry339th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingGalectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGalectin Therapeutics has received no research coverage in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.70% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 24, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 13.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GALT. Previous Next 2.4 News and Social Media Coverage News SentimentGalectin Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GALT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,520.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.66) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Galectin Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Galectin Therapeutics Stock (NASDAQ:GALT)Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Read More GALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GALT Stock News HeadlinesJuly 19, 2024 | americanbankingnews.comGalectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by StockNews.comJune 4, 2024 | globenewswire.comGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 CongressJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 18, 2024 | seekingalpha.comGalectin Therapeutics GAAP EPS of -$0.19May 15, 2024 | investorplace.comGALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business UpdateMay 13, 2024 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect ConferenceApril 30, 2024 | money.usnews.comGalectin Therapeutics IncJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 20, 2024 | morningstar.comGalectin Therapeutics Inc GALTApril 9, 2024 | markets.businessinsider.comGalectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of BelapectinApril 9, 2024 | finance.yahoo.comGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisApril 5, 2024 | investorplace.comGALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023April 3, 2024 | benzinga.comGalectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, PredictionsApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial StabilityMarch 29, 2024 | finanznachrichten.deGalectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 29, 2024 | msn.comWhat retail stores are open Easter 2024? Details on Walmart, Target, Macy's, Kohl's, moreMarch 29, 2024 | finance.yahoo.comGalectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business DevelopmentsSee More Headlines Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GALT CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+329.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,070,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-185.62% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.01) per share Price / Book-2.53Miscellaneous Outstanding Shares62,150,000Free Float29,396,000Market Cap$159.10 million OptionableOptionable Beta0.63 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Joel Lewis (Age 54)President, CEO & Director Comp: $907.72kMr. Jack W. Callicutt CPA (Age 57)CFO, Treasurer & Corporate Secretary Comp: $521.47kDr. Pol F. Boudes M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $730.33kRobert TrittGeneral CounselMr. Jeff KatstraHead of CMC & Pharmaceutical DevelopmentMs. Beth KnowlesExecutive Assistant & Officer ManagerMore ExecutivesKey CompetitorsvTv TherapeuticsNASDAQ:VTVTEnochian BiosciencesNASDAQ:ENOBLumos PharmaNASDAQ:LUMOKindred BiosciencesNASDAQ:KINAlumisNASDAQ:ALMSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 64,423 shares on 7/26/2024Ownership: 0.104%Traynor Capital Management Inc.Bought 8,164 shares on 7/24/2024Ownership: 0.069%Vanguard Group Inc.Bought 38,037 shares on 5/10/2024Ownership: 3.198%Wealthspire Advisors LLCBought 214,512 shares on 5/7/2024Ownership: 0.644%Geneos Wealth Management Inc.Sold 3,800 shares on 5/4/2024Ownership: 0.660%View All Insider TransactionsView All Institutional Transactions GALT Stock Analysis - Frequently Asked Questions How have GALT shares performed this year? Galectin Therapeutics' stock was trading at $1.66 at the beginning of 2024. Since then, GALT stock has increased by 54.2% and is now trading at $2.56. View the best growth stocks for 2024 here. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Wednesday, May, 15th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.03. Who are Galectin Therapeutics' major shareholders? Top institutional shareholders of Galectin Therapeutics include Bank of New York Mellon Corp (0.10%) and Traynor Capital Management Inc. (0.07%). Insiders that own company stock include James C Czirr, Kary Eldred, Kevin D Freeman, Jack W Callicutt, Joel Lewis, Richard A Jr Zordani, Fund LP 10X and Elissa J Schwartz. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). This page (NASDAQ:GALT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.